By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said Monday.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Indian benchmark indices Sensex and Nifty closed higher Monday, lifted by IT shares after Federal Reserve Chair Jerome Powell ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.